Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor

@article{DiCroce2002MethyltransferaseRA,
  title={Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor},
  author={Luciano Di Croce and Veronica A. Raker and Massimo Corsaro and Francesco Fazi and Mirco Fanelli and Mario Faretta and François Fuks and Francesco Lo Coco and Tony Kouzarides and Clara Nervi and Saverio Minucci and Pier Giuseppe Pelicci},
  journal={Science},
  year={2002},
  volume={295},
  pages={1079 - 1082}
}
DNA methylation of tumor suppressor genes is a frequent mechanism of transcriptional silencing in cancer. The molecular mechanisms underlying the specificity of methylation are unknown. We report here that the leukemia-promoting PML-RAR fusion protein induces gene hypermethylation and silencing by recruiting DNA methyltransferases to target promoters and that hypermethylation contributes to its leukemogenic potential. Retinoic acid treatment induces promoter demethylation, gene reexpression… 
View on AAAS
web.unicam.it
806 Citations
Highly Influential Citations
25
Background Citations
256
Methods Citations
13
Results Citations
7

806 Citations

Citation Type

Citation Type

DNA demethylation and cancer metastasis: therapeutic implications
  • M. Szyf
  • Biology, Medicine
    Expert opinion on drug discovery
  • 2008
TLDR
It is argued here that inhibition of hypomethylation might provide a new therapeutic approach to antimetastatic therapy and could be pharmacologically modulated.
DNA methyltransferase-3a interacts with p53 and represses p53-mediated gene expression
TLDR
The results presented in this study provide new understanding of tumor promotion as mediated by Dnmt3a through its interaction with p53, and suppression of the p53-mediated transcription of tumor suppressor genes.
Epigenetic gene silencing in cancer: the DNA hypermethylome.
TLDR
The importance of hypermethylation events is already in evidence at the bedside of cancer patients in the form of cancer detection markers and chemotherapy predictors, and in the approval of epigenetic drugs for the treatment of hematological malignancies, as well as in the synergy of candidate gene approaches and large-scale epigenomic technologies, such as methyl-DIP.
DNA demethylation and cancer: therapeutic implications.
DNA methylation: The nuts and bolts of repression
TLDR
The mechanisms which lead to the long‐term silencing of genes are discussed and the progression that has been made in determining the targeted mechanisms for de novo DNA methylation is surveyed.
Alterations of DNA methylation in hematologic malignancies.
Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
DNA Methylation and Demethylation as Targets for Anticancer Therapy
  • M. Szyf
  • Biology
    Biochemistry (Moscow)
  • 2005
TLDR
The emerging role of dem methylation in activation of pro-metastatic genes and the potential therapeutic implications of the demethylation machinery in metastasis are discussed.
Epigenetic gene silencing in acute promyelocytic leukemia.
DNA Methylation in Breast Cancer
TLDR
This chapter will focus on DNA methylation and the implications of coexistence of hypermethylation and hypomethylation in breast for epigenetic therapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
DNA hypermethylation in tumorigenesis: epigenetics joins genetics.
Cancer-epigenetics comes of age
TLDR
Current mechanistic understanding of the role of DNA methylation in malignant transformation is reviewed, and it is suggested Knudson's two–hit hypothesis should be expanded to include epigenetic mechanisms of gene inactivation.
DNA methylation and cancer
TLDR
The potent and specific inhibitor of DNA methylation, 5‐aza‐2′‐deoxycytidine (5‐AZA‐CdR) has been demonstrated to reactivate the expression most of these “malignancy” suppressor genes in human tumor cell lines, suggesting that epigenetics plays an important role in tumorigenesis.
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
TLDR
Although DNA methylation and histone deacetylation appear to act as synergistic layers for the silencing of genes in cancer, dense CpG island methylation is dominant for the stable maintenance of a silent state at these loci.
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
TLDR
It is shown that the predominant mammalian DNA methyltransferase, DNMT1, co-purifies with the retinoblastoma (Rb) tumour suppressor gene product, E2F1, and HDAC1 and thatDNMT1 cooperates with Rb to repress transcription from promoters containing E2f-binding sites.
Methylation-Induced Repression— Belts, Braces, and Chromatin
DNA methyltransferase Dnmt1 associates with histone deacetylase activity
TLDR
A transcriptional repression domain in Dnmt1 is identified that functions, at least partly, by recruiting histone deacetylase activity and shows homology to the repressor domain of the trithorax-related protein HRX (also known as MLL and ALL-1).
Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer.
TLDR
Methylation of the RAR-beta2 gene may be an initial step in breast carcinogenesis; treatment of cancer patients with demethylating agents followed by retinoic acid may offer a new therapeutic modality.
Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
TLDR
The use of MSP is demonstrated to identify promoter region hypermethylation changes associated with transcriptional inactivation in four important tumor suppressor genes (p16, p15, E-cadherin and von Hippel-Lindau) in human cancer.
...
1
2
3
4
5
...